MDX-2003

N/A

Report date: 2026/05/05 20:00:16

Base Information

Drug NameMDX-2003

Drug Alias NameLASER antibodyMDX-2003

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Tetraspecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD19Anti-CD20Anti-CD3 +[4]

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20T cell surface glycoprotein CD3 +[4]

Therapy Area/IndicationsPrimary mediastinal B cell lymphomaAutoimmune DiseasesWaldenstrom Macroglobulinemia +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesModeX Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesModeX Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsPrimary mediastinal B cell lymphomaAutoimmune DiseasesWaldenstrom Macroglobulinemia +[8]

Inactive IndicationsN/A

Other Information

ATC CodeN/A